UCB (BE) - Cimzia (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of joint progression in patients with rheumatoid arthritis - Drugs.com MedNews
Links shared publicly online about this topic.
- 1,089total visits
UCB (BE) - Cimzia (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of joint progression in patients with rheumatoid arthritis - Drugs.com MedNews
In adult patients with moderate to severely active rheumatoid arthritis, Cimzia provided rapid and sustained improvements in ACR responses, DAS 28 scores, HAQ-D
View full resource at drugs.com
Tags: Crohn's Disease Medication, Joint, Arthritis, Rheumatoid Arthritis, Cimzia, UCB
Most Recently Shared on June 16, 2010 at 8:45 pm By:
UCB (BE) - Cimzia (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of jo... http://bit.ly/91qZTL
Advertisement
